Percent donor EGFP or Ly5.1 expression in different cells and tissues at 62 weeks after 2 × 10 mg/kg busulfan and BMT (± 1 SEM)
Group . | Donor PBL Granulocytes . | Donor PBL B220 . | Donor PBL CD3 . | Donor BM c-kit . | Donor BM CFU-Cs . |
|---|---|---|---|---|---|
| B6-EGFP.Tg BMT, n = 5 | 19.5 ± 8.8 | 32.2 ± 7.7 | 36.4 ± 11.1 | 28.7 ± 7.1 | 38.8 ± 4.8 |
| B6-Ly5.1 BMT, n = 5 | 6.2 ± 5.9 | 12.4 ± 8.8 | 19.3 ± 12.2 | 18.2 ± 14.4 | 10.3 ± 8.1 |
Group . | Donor PBL Granulocytes . | Donor PBL B220 . | Donor PBL CD3 . | Donor BM c-kit . | Donor BM CFU-Cs . |
|---|---|---|---|---|---|
| B6-EGFP.Tg BMT, n = 5 | 19.5 ± 8.8 | 32.2 ± 7.7 | 36.4 ± 11.1 | 28.7 ± 7.1 | 38.8 ± 4.8 |
| B6-Ly5.1 BMT, n = 5 | 6.2 ± 5.9 | 12.4 ± 8.8 | 19.3 ± 12.2 | 18.2 ± 14.4 | 10.3 ± 8.1 |
Corrected for EGFP and Ly5.1 expression in respective B6-EGFP.Tg and B6-Ly5.1 control mice.